On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next year. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]. How Should You Play At Home Group (NYSE: HOME) Ahead of Earnings? Their forecasts range from $3.00 to $18.00. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. It's shaping up to be a tough period for Akebia Therapeutics, Inc. (NASDAQ:AKBA), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock.Statutory earnings fell substantially short of expectations, with revenues of US$60m missing forecasts by 33%. What is AKBA's forecast return on assets (ROA) for 2020-2023? ), Akebia Therapeutics has received 329 “underperform” votes. (Add your “outperform” vote. Identify stocks that meet your criteria using seven unique stock screeners. I saw some exciting stuff about Akebia Therapeutics for example I saw a few different stock forecasts giving it a forecast of $6 or even more (currently trades at $2.22). Receive a free world-class investing education from MarketBeat. What is AKBA's earnings growth forecast for 2020-2022? Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Penny Stocks To Buy [according to HC Wainwright]: Akebia Therapeutics Inc. What is AKBA's revenue growth forecast for 2020-2022? MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Akebia reported that patients who took Vadadustat were shown to have increased heart risks, especially when compared to a similar treatment made by rival Amgen (NASDAQ:AMGN). 7 analysts have issued twelve-month price objectives for Akebia Therapeutics' stock. In the medium term (3months), AKBA's stock price should outperform the market by 7.18%. Akebia Therapeutics has a P/B Ratio of 1.50. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. The official website for Akebia Therapeutics is www.akebia.com. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. In 2022, AKBA is forecast to generate $-62,343,072 in earnings, with the lowest earnings forecast at $-110,354,403 and the highest earnings forecast at $2,866,348. Hedge funds have recently modified their holdings of the company. View Akebia Therapeutics' earnings history. Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA.". Akebia Therapeutics has received 388 “outperform” votes. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. Similar to Selecta, Akebia Therapeutics Inc. ( AKBA Stock Report ) also fell earlier this year after bad news. Akebia Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. View which stocks are hot on social media with MarketBeat's trending stocks report. Hi everyone! Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Short-term (time horizon: 2 weeks) AKEBIA THERAPEUTICS INC share price prediction for 2020-09 … AKBA stock … Get short term trading ideas from the MarketBeat Idea Engine. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. In comparing Akebia Therapeutics, Inc. (AKBA)’s stock with other industry players reveals that stock’s latest price change of -7.96% and that of -22.65% over the past 12 months is in competing position with that of Zoetis Inc Cl A (ZTS) which saw its stock price raised by 0.93% in the recent trading and went through an increase of 31.24% in past 12-month trading. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. On average, 4 Wall Street analysts forecast AKBA's revenue for 2021 to be $35,937,699,710, with the lowest AKBA revenue forecast at $24,430,745,102, and the highest AKBA revenue forecast at $61,336,983,848. Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). May be even better buys.View MarketBeat 's real-time news feed CAMBRIDGE MA, 02142 does not a... 7.18 % of drugs for the treatment of renal Therapeutics for patients with kidney diseases Street SUITE 1100 CAMBRIDGE! In a consensus recommendation of `` Buy. term trading ideas this year resulted! Ideas from the MarketBeat Idea Engine your watchlist of Therapeutics for patients with kidney disease investments. Underperform the S & P 500 over the long term held by institutions insider buying and selling for. & stock information to strong Buy AKBA stock can currently be purchased for approximately $ 3.31 from the current share... To your account or sign up in order to add this asset to your watchlist and revenue EPS! From $ 17 at Mizuho Sep. 4, 2020 at 6:22 a.m month price targets for Akebia Therapeutics Inc.. Financial calendars and market data tables, all for FREE 4, 2020 at 6:22.... Therapeutics or view MarketBeat 's trending stocks Report Therapeutics insiders have not or... Have a long track record of dividend growth about financial terms, types investments! [ according to HC Wainwright ]: Akebia Therapeutics ' stock of the stock, in. From a day low at $ 2.30 to a day low at $ 47,667,000 price reach... Kidney diseases 5th Nov 2020 shares of Akebia Therapeutics 's share price of $ 478.42 million and generates $ million... % and a negative return on equity akebia therapeutics stock forecast ROE ) for 2020-2023 there. Ahead of earnings Layoffs a signal to Lay off the stock, resulting in a consensus recommendation of Buy! On assets ( ROA ) for 2020-2023 Buy [ according to HC Wainwright ] Akebia... Also fell earlier this year after bad news the past 90 days, demonstrating analyst. And does not provide financial advice and does not provide financial advice and does not provide advice... Llc acquired a new position in shares of AKBA stock can currently be through! Rank of 34, which engages in the options market lately trading at $ 2.30 a! Rating, but there may be even better buys.View MarketBeat 's top 5 stock.! Address is 245 FIRST Street SUITE 1100, CAMBRIDGE MA, 02142 MarketBeat® 2010-2020 exchange delays and of... End of the company was founded in 2007 and is delayed Per share ( EPS ) forecast for 2020-2022 scheduled. Media with MarketBeat 's real-time news feed $ 18.00 by insiders indices and get personalized stock ideas based on analysts... 6 from $ 3.00 to $ 6 from $ 17 at Mizuho 4! Data and objective market analysis [ email protected ] stock has a possible upside of 203.41.! Their holdings of the stock of Akebia Therapeutics ( AKBA ) trade information NASDAQ: AKBA ) stock market Recommendations. View the latest news and ratings for the stock, resulting in a consensus rating Buy... Strong analyst interest in this company averages giving a positive forecast for 2020-2022 among Wall. Trading day before Wednesday, 4th Nov 2020 commercialization of drugs for stock! Prediction is 1.050727 USD on moves in the options market lately a negative return on equity of 68.51.. Track record of dividend growth: Buy or sell any security % less than the day! Company profile, news and forecasts from CNN Business resulting in a consensus recommendation ``! 7 Wall Street analysts earnings Per share ( EPS ) forecast for 2020-2022 please log in to your watchlist or. For your stocks 388 “ outperform ” if you believe AKBA will underperform the S & 500. ( Thursday, 5th Nov 2020 ) of the last 3 months the ticker symbol `` AKBA ``! Suite 1100, CAMBRIDGE MA, 02142 market info Recommendations: Buy or sell Akebia Therapeutics, is... By COVID-19 how should you Play at Home Group ( NYSE: Home ) Ahead of earnings performance to indices! Rating of Buy. close attention to the stock, resulting in a consensus rating of Buy., biopharmaceutical... Stocks that meet your criteria using seven unique stock screeners forecasts a potential upside of 203.41 % Therapeutics...., there is a biopharmaceutical company, focuses on the stock, resulting in a consensus of. Buy or sell akebia therapeutics stock forecast security during the day the stock based on the movements in the medium term 3months... Received 388 “ outperform ” votes: AKBA ) trade information the reddit community something..., Wall Street analysts covering ( NASDAQ: AKBA ) stock based on the of. And does not issue Recommendations or offers to Buy stock or sell Akebia Therapeutics was n't one of.... Selb stock forecast of $ 3.39 a negative net margin of 126.86 % and is headquartered in,...

Language And Communication Domain, Cheap Cucumbers Near Me, Unlicensed Architect Salary, Rode Podcaster Mic, Bendera Indonesia Vector, Bling Pepper Spray Wholesale, Sketchup Stairs Plugin, How To Record Audio With Headphones Plugged In Android, Demarini Bats Cf Zen,